Vertex Pharmaceuticals (VRTX) Q3 2025 10-Q Quarterly Report
Vertex Pharmaceuticals (VRTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Vertex Pharmaceuticals Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $3.1B in Q3 2025, up 11% from $2.8B in Q3 2024, driven by TRIKAFTA/KAFTRIO and new launches including ALYFTREK and JOURNAVX
- • Operating margin improved: income from operations $1.19B (39% margin) in Q3 2025 vs $1.12B (40% margin) in Q3 2024, cost of sales down to 13.5% from 14.2%
- • Best segment: CF products (TRIKAFTA/KAFTRIO $2.65B, up 3% YoY in Q3) with growing patient demand; Worst: "Other product revenues" down 6% YoY to $176M, partly due to lower CASGEVY sales growth
- • Cash, cash equivalents, and marketable securities increased 7% to $12.0B as of Sep 30, 2025; net cash from operating activities $3.13B in nine months vs negative $1.08B prior year; capital deployment includes $2.18B in repurchases
- • Near-term outlook notes ongoing CF patient growth, expanded reimbursement for CASGEVY in Europe/Middle East, continued rollout of JOURNAVX; risks include royalty litigation, drug pricing reforms, and pipeline development uncertainties
Risk Factors
- • No newly added risk factors this quarter; no material changes from 2024 10-K risk disclosures
- • Carryforward regulatory risk: challenges obtaining accelerated approvals and maintaining reimbursement coverage
- • Legal risk: ongoing litigation and arbitration related to products and activities remain unresolved
- • Market risk: dependence on growth of cystic fibrosis (CF) patient population and reimbursement environment
- • Financial risk: exposure to foreign currency fluctuations managed through foreign currency management program
Vertex Pharmaceuticals Q3 2025 Quarterly FinancialsXBRL
Revenue
$3.1B
▲ +11.0% YoY▲ +3.8% QoQ
Net Income
$1.1B
▲ +3.6% YoY▲ +4.8% QoQ
Net Margin
35.2%
▼ -251bp YoY▲ +36bp QoQ
Source: XBRL data from Vertex Pharmaceuticals Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Vertex Pharmaceuticals Quarterly Reports
Get deeper insights on Vertex Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.